Health Catalyst Raises PT to $10, Maintains 'Buy' Rating

sábado, 26 de julio de 2025, 4:58 pm ET1 min de lectura
HCAT--
WFC--

Wells Fargo raised its price target for Health Catalyst to $10, maintaining a 'Buy' rating. The analyst believes the company is undervalued compared to peers, with expected growth in bookings, revenue visibility, and EBITDA growth. Strong customer loyalty and revenue base are also expected to drive growth.

Health Catalyst Raises PT to $10, Maintains 'Buy' Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios